Cite
HARVARD Citation
Tanaka, I. et al. (2019). Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations. Lung cancer. pp. 169-171. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Tanaka, I. et al. (2019). Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations. Lung cancer. pp. 169-171. [Online].